+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

R-DA-EPOCH improves the outcome over that of the R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high IPI, but not for double expressor lymphoma



R-DA-EPOCH improves the outcome over that of the R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high IPI, but not for double expressor lymphoma



Hematological Oncology 35: 336-337




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065040086

Download citation: RISBibTeXText

DOI: 10.1002/hon.2439_82


Related references

DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma. Journal of Cancer Research and Clinical Oncology 145(1): 117-127, 2019

A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution. Oncotarget 7(27): 41242-41250, 2016

Dose-dense rituximab improves outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL): Results of the DENSE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL). 2007

Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clinical Cancer Research 16(8): 2435-2442, 2010

Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Journal of Clinical Oncology 26(15_Suppl): 8508-8508, 2016

Serum soluble tumor necrosis factor receptor 1 level is associated with the outcome of diffuse large B-cell lymphoma patients treated with the CHOP or R-CHOP regimen. Journal of Clinical and Experimental Hematopathology 54(2): 117-127, 2014

R-CHOP-14 in patients with diffuse large-B-cell lymphoma (DLBCL) younger than 70 years: A multicentric and prospective study. Journal of Clinical Oncology 24(18_Suppl): 7592-7592, 2016

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101(11): 4279-4284, 2003

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients. The Scientific World Journal 2012: 1-7, 2012

Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients. Thescientificworldjournal 2012: 897178, 2012

Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma. Ai Zheng 24(12): 1498-1502, 2005

Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(4): 933-937, 2008

Prognostic value of serum soluble IL2 receptor (sIL2R) level in patients with diffuse large B cell lymphoma (DLBCL), treated with CHOP or R-CHOP based therapy. 2007

Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC , BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study. Cancer Management and Research 11: 1363-1372, 2019

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. Journal of Clinical Oncology 16(1): 27-34, 1998